EMEA-000366-PIP04-12
Key facts
| Invented name |
Humira
|
| Active substance |
adalimumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0121/2013
|
| PIP number |
EMEA-000366-PIP04-12
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of hidradenitis suppurativa
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AbbVie Ltd
E-mail: paediatricteam@abbvie.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-000366-PIP04-12
|
| Compliance opinion date |
01/04/2016
|
| Compliance outcome |
positive
|